The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for a new weekly transdermal patch formulation (once-weekly administration formulation) of Eisai's Alzheimer’s treatment, Aricept for review.
Aricept transdermal patch NDA, if approved, is expected to be marketed by Eisai Inc, Easai’s US subsidiary, where it will co-promote the patch in collaboration with Pfizer.
Easai said that the new Aricept transdermal patch is developed by Teikoku Pharma USA, under an agreement signed between Eisai and its parent company Teikoku Seiyaku in 2009.
Aricept transdermal patch employs a drug delivery system to provide a potential new treatment option to Alzheimer’s disease patients who have trouble swallowing as well as to reduce the burden on caregivers and family members who administer daily medication.